See today's BioWorld
To read the full story, subscribe or sign in.

Peptimmune, Novartis Sign $500M Deal for MS Drug

Jan. 20, 2009
By Catherine Hollingsworth
Peptimmune Inc., a privately held U.S. biotechnology company, has granted Novartis AG an exclusive option to license its drug candidate for multiple sclerosis, PI-2301. (BioWorld Today)
BioWorld